Evidence map›Paper›PMID 29379507›Full record

ArticleFrontiers in immunology2017

High Antigen Dose Is Detrimental to Post-Exposure Vaccine Protection against Tuberculosis.

Rolf Billeskov, Thomas Lindenstrøm, Joshua Woodworth, Cristina Vilaplana, Pere-Joan Cardona, Joseph P Cassidy, Rasmus Mortensen, Else Marie Agger, Peter Andersen

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 40 citations in OpenAlex.

  1. Trial
  2. Increase of Dose Associated With Decrease in Protection Against Controlled Human Malaria Infection by PfSPZ Vaccine in Tanzanian Adults.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020
    Trial
  3. Development of a NovelVaccines · 2026
    Article
  4. A novel and safe SmartCapFrontiers in immunology · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Advancing Adjuvants forFrontiers in immunology · 2021
    Review
  17. Immunization withJournal of immunology (Baltimore, Md. : 1950) · 2020
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

Rolf BilleskovDepartment of Infectious Disease Immunology, Statens Serum Institut, Copenhagen, Denmark.
Thomas LindenstrømDepartment of Infectious Disease Immunology, Statens Serum Institut, Copenhagen, Denmark.
Joshua WoodworthDepartment of Infectious Disease Immunology, Statens Serum Institut, Copenhagen, Denmark.
Cristina VilaplanaUnitat de Tuberculosi Experimental, Institut per a la Investigació en Ciències de la Salut Germans Trias I Pujol, CIBER Enfermedades Respiratorias, Universitat Autònoma de Barcelona, Badalona, Barcelona, Spain.
Pere-Joan CardonaUnitat de Tuberculosi Experimental, Institut per a la Investigació en Ciències de la Salut Germans Trias I Pujol, CIBER Enfermedades Respiratorias, Universitat Autònoma de Barcelona, Badalona, Barcelona, Spain.
Joseph P CassidyVeterinary Sciences Centre, School of Veterinary Medicine, University College Dublin, Belfield, Dublin, Ireland.
Rasmus MortensenDepartment of Infectious Disease Immunology, Statens Serum Institut, Copenhagen, Denmark.
Else Marie AggerDepartment of Infectious Disease Immunology, Statens Serum Institut, Copenhagen, Denmark.
Peter AndersenDepartment of Infectious Disease Immunology, Statens Serum Institut, Copenhagen, Denmark.
Statens Serum Institut · DKCentro de Investigación Biomédica en Red de Enfermedades Respiratorias · ESInstitut d'Investigació en Ciències de la Salut Germans Trias i Pujol · ESUniversity College Dublin · IE

Funding

Eliciting lung-localized CD4 T cell responses against Mycobacterium tuberculosis in preventive and post-exposure settingsR01AI134246 · NIAID · SEATTLE CHILDREN'S HOSPITAL · PI LINDENSTRØM, THOMAS, URDAHL, KEVIN B · 2017 to 2021
$3.3M
NIAID NIH HHS R01 AI134246
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

adjuvantCAF01functional avidityH56post-exposure vaccinationT cell qualitytuberculosisvaccine dose

Identifiers

PMID29379507
PMCPMC5775287
OpenAlexW2782643628

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.